| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND Little is known on how the coronavirus disease-2019 (COVID-2019) has impacted the management of people with type 2 diabetes mellitus (T2DM). Therefore, the aim of this study was to estimate the proportion of individuals with T2DM undergoing changes in glucose-lowering therapy in 2019 and 2020. METHOD Individuals with T2DM with at least one consultation in one of 940 general (including diabetologist) practices in Germany between January and July 2019 (N = 79 268) and between January and July 2020 (N = 85 046) were included. Therapy changes corresponded to the prescription of new glucose-lowering drugs with or without the discontinuation of previous treatments (switch and add-on therapy, respectively). The number of T2DM patients with at least one medication regimen change was calculated for the period between January 1 and March 14 and the period between March 15 and July 31 in 2019 and 2020. March 2020 corresponded to the beginning of the lockdown in Germany. RESULTS Overall, there was a decrease in the number of persons with ≥1 medication regimen change in March 15/July 312 019 compared with March 15/July 312 020 (dipeptidyl peptidase-4 inhibitors [DPP-4i]: -15%; sodium-glucose cotransporter 2 inhibitors [SGLT2i]: -3%; glucagon-like peptide-1 receptor agonists [GLP-1 RA]: 0%; other oral glucose-lowering drugs: -6%; and insulin: -21%). CONCLUSIONS The COVID-19 pandemic had a strong impact on glucose-lowering drug use in T2DM patients in Germany. More research is warranted to further investigate the treatment and management of T2DM individuals during the COVID-19 era in Germany and elsewhere. This article is protected by copyright. All rights reserved.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
-
Diabetes,_obesity_&_metabolism
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Change in glucose-lowering medication regimen in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}